Form 4: Bionano Genomics CEO Erik Holmlin Reports Changes in Beneficial Ownership After Stock Split and RSU Vesting

CEO Erik Holmlin reports changes in Bionano Genomics beneficial ownership due to a stock split, RSU vesting, and tax withholding.

Summary

• On February 19, 2025, Erik Holmlin, CEO of Bionano Genomics, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
• The changes are due to the withholding of 51 shares for tax obligations related to vested Restricted Stock Units (RSUs) on February 15, 2025.
• Additionally, the filing reflects a 1-for-60 reverse stock split that occurred on January 24, 2025, which reduced Holmlin's holdings by 120,428 shares.
• Holmlin's holdings include shares held directly and indirectly through a Traditional IRA.
• He also acquired 2 shares under the Issuer's 2018 Employee Stock Purchase Plan on June 10, 2024 (as adjusted for the January 2025 Reverse Stock Split).

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, so the sentiment is neutral.

Industry Context

Form 4 filings are standard practice for company insiders to report changes in their ownership of company stock, ensuring transparency and compliance with SEC regulations.

Stakeholder Impact

• The reverse stock split impacts all shareholders by reducing the number of outstanding shares and increasing the price per share.

Key Dates

Keywords

Form 4, Beneficial Ownership, Bionano Genomics, BNGO, Holmlin, Stock Split, RSU, Tax Withholding, Employee Stock Purchase Plan